INNA SABIRZHANOVA: Open Payments
NPI 1750061479 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$371 in 15 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $268 · 2025 $371
Food & beverage: $371
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $99 |
| Janssen Biotech, Inc. | 3 | $87 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $55 |
| Incyte Corporation | 2 | $52 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Merck Sharp & Dohme LLC | 1 | $17 |
Products named: TECVAYLI, Stivarga, TALVEY, OPDIVO, KEYTRUDA.
Industry payments across MD — which companies pay providers there.
